CBP Antikörper (AA 2217-2442)
Kurzübersicht für CBP Antikörper (AA 2217-2442) (ABIN7148671)
Target
Alle CBP (CREBBP) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 2217-2442
-
Kreuzreaktivität
- Human
-
Aufreinigung
- >95%, Protein G purified
-
Immunogen
- Recombinant Human CREB-binding protein (2217-2442AA)
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200,
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4 -
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C,-80 °C
-
Informationen zur Lagerung
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
-
- CBP (CREBBP) (CREB Binding Protein (CREBBP))
-
Andere Bezeichnung
- CREBBP
-
Hintergrund
-
Background: Acetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 and FOXO1. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1 heterodimers. Acetylates PCNA, acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER) (PubMed:24939902).
Aliases: CBP antibody, CBP_HUMAN antibody, CREB binding protein antibody, CREB-binding protein antibody, Crebbp antibody, Cyclic AMP responsive enhancer binding protein antibody, KAT3A antibody, RSTS antibody, RTS antibody, Rubinstein Taybi syndrome antibody
-
UniProt
- Q92793
-
Pathways
- T-Zell Rezeptor Signalweg, Interferon-gamma Pathway, Stem Cell Maintenance, Chromatin Binding, Regulation of Lipid Metabolism by PPARalpha
Target
-